P834 Non-Invasive Management of Non-Alcoholic Fatty Liver Disease

Gallego‐Durán, Rocío; Cerro-Salido, P.; Pareja, M.J.; Ranchal, Isidora; Rojas, Liliana; Aznar, Rafael; Bugianesi, E.; Crespo, Javier; Arias-Loste, María Teresa; Abad, Javier; Soto, Salvador Navarro; Aparcero, R.; Moreno, I.; Calleja, J.L.; Iacono, Oreste Lo; Andrade, R.; Gómez-González, Emilio; Romero‐Gómez, Manuel

doi:10.1016/s0168-8278(14)60995-8

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two-dimensional SWE shows promise in the non-invasive staging of liver fibrosis in patients with NAFLD, although cut-offs need to be optimised [82]. Additionally, there is the LiverMultiScanTM which uses multiparametric MRI to provide quantitative measures of liver fat, iron, fibrosis and inflammation [83] and the DeMILI® (Detection of Metabolic-Induced Liver Injury) software, which can detect NASH and predict significant fibrosis [84]. Both the LiverMultiScanTM and DeMILI have been utilised in the Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) project, which aims to develop and validate qualification biomarkers that diagnose and/or monitor NAFLD/NASH progression and fibrosis stage [85].…”

Section: Which Screening Tests To Use?mentioning

confidence: 99%

Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice

Augustín

Ahmed

Alkhouri

et al. 2020

JGLD

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) prevalence has increased in the past two decades, resulting in a significant but under-recognised public health burden. This impacts the prevalence of advanced fibrosis, end-stage liver disease and associated extrahepatic manifestations. To understand the challenges in recognising patients with advanced fibrosis due to NASH and develop a standardised approach to screen these patients, the authors of this document provided their opinions and expertise from practice and published evidence to identify key challenges and current approaches for diagnosing NASH. The severity of liver fibrosis due to NASH is the main indicator of associated morbidity and mortality outcomes. Therefore, identifying patients with, or at risk of, advanced fibrosis due to NASH and linking them to appropriate care is critical. This can be challenging due to a lack of awareness of NASH among healthcare professionals and a lack of standardised protocols for identifying patients. Simple noninvasive tests may provide an opportunity to facilitate early identification of these patients. This article proposes a simple, universally applicable diagnostic algorithm for use in clinical practice, that includes sequential use of noninvasive tests, ideally a biological marker and an imaging technique, which may help to facilitate early diagnosis of these patients. In the opinion of the authors, early detection of advanced fibrosis is fundamental in the efforts to halt the progression of NASH and diagnostic algorithms may facilitate pre-emptive interventions to curtail the disease.

show abstract

Section: Which Screening Tests To Use?mentioning

confidence: 99%